Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Pharmaceutical will participate in three upcoming investor conferences: the Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, and the Bank of America Global Healthcare Conference. Eric Crombez, Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in fireside chats and host 1x1 meetings at these events. The live and archived webcast of the fireside chats will be accessible from the company's website.

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare genetic disease therapies, has announced its participation in three major investor conferences in September 2025. The company's leadership, including Chief Medical Officer Eric Crombez, M.D., and Chief Financial Officer Howard Horn, will participate in fireside chats and host one-on-one meetings at the Cantor Global Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference (September 23). All fireside chat sessions will be available via webcast on the company's investor relations website.

The Cantor Global Healthcare Conference 2025 will take place in New York, NY, on September 4. The Morgan Stanley 23rd Annual Global Healthcare Conference will also be held in New York, NY, on September 9. The Bank of America Global Healthcare Conference is scheduled for September 23 in London, UK. The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

Ultragenyx Pharmaceutical is committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

References:
[1] https://www.stocktitan.net/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-lirvf6qfbfoa.html